Inclusion Criteria:

- male or female at least 18 years of age, up to 99 years of age

- able to give verbal and written informed consent

- clinically diagnosed cancer with multiple cutaneous metastases that are able to be
biopsied. The subject may or may not be on concomitant cancer treatments/have
internal metastases.

- for women of childbearing potential (WOCBP) or in men whose partners may become
pregnant, willingness to use an acceptable method of contraception to prevent
pregnancy for the duration of the study (while receiving study medication and for one
month following the last dose of study medication). Acceptable forms of contraception
are listed in the informed consent form.

- must have a negative urine pregnancy test (for WOCBP)

- must be willing and able to have the therapy applied by the investigator, must be
willing and able to self-apply the therapy, and must be willing and able to comply
with study instructions and return for required clinic visits.

Exclusion Criteria:

- subjects taking any of the following systemic or topical therapies within 4 weeks of
enrollment: corticosteroids, immunosuppressants, and/or any other medications that
may affect the outcome of the study

- subjects who have active localized or systemic medical conditions that, in the
opinion of the investigator, would preclude or make unsafe their participation in the
study

- subjects with any underlying diseases or dermatological conditions of the affected
areas that require the use of interfering topical or systemic therapy

- subjects who are nursing mothers, pregnant, or planning to become pregnant at anytime
during the course of the study or within 30 days of study completion

- subjects who are unable to comply with study procedures, communicate effectively,
cooperate with the investigator, or are unable to understand the study

- history, physical, social, or lab findings suggestive of any medical or psychological
condition that would, in the opinion of the PI, make the candidate ineligible for the
study

- HIV positive as determined by self-reported history and/or a HIV point-of-care test
at screening